1. Home
  2. AGIO vs CXM Comparison

AGIO vs CXM Comparison

Compare AGIO & CXM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$28.92

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Sprinklr Inc.

CXM

Sprinklr Inc.

HOLD

Current Price

$7.71

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
CXM
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
AGIO
CXM
Price
$28.92
$7.71
Analyst Decision
Buy
Hold
Analyst Count
8
10
Target Price
$32.13
$10.00
AVG Volume (30 Days)
1.5M
2.5M
Earning Date
02-12-2026
12-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
180.38
EPS
N/A
0.42
Revenue
$44,791,000.00
$839,147,000.00
Revenue This Year
$28.75
$6.22
Revenue Next Year
$139.45
$4.49
P/E Ratio
N/A
$18.12
Revenue Growth
36.26
6.48
52 Week Low
$22.24
$6.75
52 Week High
$46.00
$9.69

Technical Indicators

Market Signals
Indicator
AGIO
CXM
Relative Strength Index (RSI) 50.24 51.18
Support Level $24.16 $7.61
Resistance Level $27.95 $7.98
Average True Range (ATR) 1.20 0.19
MACD 0.50 -0.02
Stochastic Oscillator 82.82 19.17

Price Performance

Historical Comparison
AGIO
CXM

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About CXM Sprinklr Inc.

Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.

Share on Social Networks: